Wave Life Sciences Ltd.
Wave Life Sciences Ltd. Completes Additional Share Sale in Public Offering
Summary
Wave Life Sciences Ltd. completed the sale of an additional 3,000,000 ordinary shares on January 4, 2024, after underwriters exercised their option to purchase more shares. This follows the initial public offering of 20,000,000 shares at $5.00 per share, which closed on December 11, 2023. The total shares sold in the offering amount to 23,000,000, with the company receiving gross proceeds of $115 million.
Get alerts for WVE
Be first to know when Wave Life Sciences Ltd. files with the SEC.
Filing Categories
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd. is a biotechnology company engaged in the research and development of stereopure nucleic acid therapies. The primary focus of Wave Life Sciences is to leverage its unique platform to design and optimize therapies that modulate RNA to address genetic diseases. This involves developing treatments with high specificity and efficacy, potentially offering advantages over traditional nucleic acid therapies. The company targets a range of serious diseases, including those related to the central nervous system, with its innovative therapies. Wave Life Sciences plays a significant role in the biopharmaceutical industry by expanding the potential of gene medicine. Its work has implications for sectors such as healthcare and pharmaceuticals, especially in developing new treatment modalities for unmet medical needs. The company's research and development efforts are geared towards delivering transformational outcomes for patients, positioning it as a pioneer in the evolving field of genetic medicine. Wave Life Sciences Ltd. claims a critical space within the market for its advancements in precision medicine and continues to collaborate with various stakeholders to push the boundaries of therapeutic development.
Official SEC Documents